Musculoskeletal · PANCE / PANRE

Gout

Acute monoarticular crystal arthritis from monosodium urate deposition; classically the first MTP joint.

Also known as: gout, podagra, urate arthropathy, hyperuricemia

Overview

Crystal-induced arthropathy caused by deposition of monosodium urate (MSU) crystals in joints, tendons, and soft tissues, triggered by sustained hyperuricemia. Manifests as recurrent acute monoarticular flares progressing in some patients to chronic tophaceous disease.

Epidemiology

Most common inflammatory arthritis in men. Prevalence ~4% of US adults; rises with age, obesity, metabolic syndrome, and CKD. Premenopausal women relatively protected (estrogen is uricosuric).

🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Gout outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Free to start · No credit card · Cancel anytime

Risk factors

  • Male sex, age >40
  • Hyperuricemia (serum urate >6.8 mg/dL — saturation point)
  • Diet: red meat, shellfish, organ meats, beer, high-fructose corn syrup
  • Alcohol (especially beer)
  • Chronic kidney disease (decreased urate excretion)
  • Diuretics (thiazide, loop), low-dose aspirin, cyclosporine, tacrolimus
  • Obesity, metabolic syndrome, hypertension
  • Tumor lysis syndrome, psoriasis, hemolysis (overproduction)
  • Lead nephropathy (saturnine gout)

Pathophysiology

Sustained serum urate above the saturation threshold (~6.8 mg/dL at 37 °C) leads to MSU crystal formation in cooler peripheral tissues. Crystals are phagocytosed by macrophages, activating the NLRP3 inflammasome and releasing IL-1β, which drives neutrophil influx and acute inflammation. Chronic deposition produces tophi and erosive arthropathy.

Clinical presentation

Symptoms

  • Sudden onset (often nocturnal) severe monoarticular pain peaking within 12-24 hours
  • Classic site: first metatarsophalangeal joint (podagra) in ~50% of first attacks
  • Other sites: midfoot, ankle, knee, wrist, elbow, fingers
  • Self-limited untreated attacks resolve in 7-14 days
  • Recurrent flares with eventual chronic polyarticular involvement

Signs / physical exam

  • Exquisitely tender, warm, swollen, erythematous joint
  • Skin may desquamate as attack resolves
  • Low-grade fever during severe attacks
  • Tophi — firm, painless subcutaneous nodules on extensor surfaces, helix of ear, Achilles tendon, finger pulps (chronic disease)

Classic findings

Podagra: red, hot, exquisitely tender first MTP joint.

Differential diagnosis

  • Septic arthritis — Fever, prior bacteremia, prosthetic joint; can coexist with gout — must perform arthrocentesis with Gram stain and culture in every suspected first gout attack
  • Pseudogout (CPPD) — Knee or wrist most common; rhomboid positively birefringent crystals; chondrocalcinosis on radiograph
  • Cellulitis — Diffuse erythema without joint capsule signs; no crystals; arthrocentesis distinguishes
  • Rheumatoid arthritis flare — Polyarticular, symmetric; tophi may be confused with rheumatoid nodules
  • Reactive arthritis — Recent GU/GI infection; oligoarticular, lower-extremity
  • Trauma / fracture — Mechanism and radiographs distinguish

Diagnostic workup

Diagnostic criteria

Definitive: identification of MSU crystals in joint fluid or tophus. 2015 ACR/EULAR classification criteria available for cases where aspiration is not feasible.

Labs

  • Arthrocentesis with polarized microscopy — gold standard: needle-shaped, NEGATIVELY birefringent MSU crystals; inflammatory fluid (WBC 20,000-100,000, neutrophil-predominant)
  • Gram stain and culture on every arthrocentesis to exclude concurrent septic arthritis
  • Serum urate (may be NORMAL during acute attack; recheck 2-4 weeks later)
  • CBC, ESR/CRP often elevated
  • BMP, urate excretion (24-h urine urate) to classify under- vs over-excretors if planning therapy
  • Lipid panel and A1c — frequent comorbidities

Imaging

  • Plain radiographs — early attacks usually normal; chronic disease shows 'rat-bite' periarticular erosions with overhanging edges, sparing of joint space until late
  • Dual-energy CT (DECT) — color-codes MSU deposition (research/specialty use)
  • Ultrasound — 'double-contour sign' along articular cartilage is highly specific

Diagnostic algorithm

FeatureGout (MSU)Pseudogout (CPPD)
Typical joint1st MTP (podagra), midfoot, ankle, kneeKnee, wrist (also MCPs, shoulder)
Crystal shapeNeedle-shapedRhomboid
BirefringenceNegative (yellow parallel)Positive (blue parallel)
Color under polarized lightYellow when parallel to compensatorBlue when parallel to compensator
RadiographRat-bite erosions with overhanging edges; preserved joint space (early)Chondrocalcinosis (linear calcification within cartilage)
TriggersDiet, alcohol, diuretics, surgery, dehydrationTrauma, surgery, hospital admission, hyperparathyroidism, hemochromatosis
Long-term therapyAllopurinol, febuxostat, probenecidNo urate-lowering; treat underlying metabolic disease
Gout vs pseudogout — polarized microscopy is the definitive distinction.

Treatment

First-line

  • Acute flare (treat ASAP, ideally within 24 h of onset):
  • • NSAIDs — indomethacin, naproxen, ibuprofen at full anti-inflammatory dose × 5-7 days (avoid in CKD, HF, GI bleed)
  • • Colchicine 1.2 mg PO, then 0.6 mg one hour later, then 0.6 mg daily-BID (renal dose adjustment; avoid in severe CKD or with strong CYP3A4/P-gp inhibitors)
  • • Glucocorticoids — prednisone 30-40 mg/day × 5 days with taper, or intra-articular triamcinolone (preferred if monoarticular and septic excluded)
  • • IL-1 inhibitor — anakinra or canakinumab for refractory or contraindication to others
  • Do NOT start urate-lowering therapy during an attack, but do NOT stop it if already on it

Complications

  • Chronic tophaceous gout with joint destruction and disability
  • Urate nephrolithiasis
  • Chronic urate nephropathy
  • Coexistent metabolic syndrome and cardiovascular disease
  • Drug reactions: allopurinol hypersensitivity (SJS/TEN), febuxostat CV events
  • Septic arthritis can coexist with gout — never assume monomicrobial

PANCE pearls

  • Serum urate may be normal during an acute attack — do not use it to rule out gout.
  • First arthrocentesis MUST include Gram stain and culture; septic arthritis and gout coexist.
  • Negatively birefringent (yellow when parallel to red compensator) needle-shaped crystals = gout. Positively birefringent rhomboid crystals = pseudogout (mnemonic: 'PPP' — Positive Pseudogout, Parallel).
  • Initiating allopurinol during a flare can prolong it — but if a patient is already on it, continue without interruption.
  • Always co-prescribe anti-inflammatory prophylaxis (colchicine or low-dose NSAID) for 3-6 months when starting urate-lowering therapy to prevent mobilization flares.

References

  • ACR 2020 — 2020 American College of Rheumatology Guideline for the Management of Gout (FitzGerald et al., Arthritis Care Res 2020)
  • ACR/EULAR 2015 — 2015 Gout Classification Criteria (Neogi et al., Arthritis Rheumatol 2015)
  • EULAR 2016 — 2016 Updated EULAR Evidence-Based Recommendations for the Management of Gout (Richette et al., Ann Rheum Dis 2017)

Practice Musculoskeletal questions on FirstPassPA

Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Start studying free → Browse all 514 diagnoses

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.